SCHEMBL6466211

SCHEMBL6466211

CCOC(=O)c1c(C)c(-c2ccc(C(N)=O)cc2)c(C)n1Cc1ccc(F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.46
KDM4E B2RXH2 1/20 0.45
PKM P14618 1/20 0.45
ALDH1A1 P00352 1/20 0.43
POLB P06746 1/20 0.43
HTT P42858 1/20 0.43
MDM4 O15151 1/20 0.43
MDM2 Q00987 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
AR P10275 1/20 0.41
MAOB P27338 1/20 0.41
PARP10 Q53GL7 1/20 0.41
GRM6 O15303 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
GPR55 Q9Y2T6 1/20 0.41
SSTR5 P35346 1/20 0.41
GRM2 Q14416 1/20 0.41
F10 P00742 1/20 0.40
MAPK14 Q16539 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7052030 0.88 AR (0.45) MAPTKDM4EALDH1A1POLBL3MBTL1
SCHEMBL6464447 0.85 AR (0.53) MAPTKDM4EPKMALDH1A1POLB
SCHEMBL6469416 0.78 MAPT (0.51) MAPTKDM4EPKMALDH1A1POLB
SCHEMBL6465920 0.73 AR (0.76) MAPTPOLBARMEN1KMT2A
SCHEMBL6466727 0.71 AR (0.60) MAPTKDM4EALDH1A1HTTAR
SCHEMBL6468233 0.70 AR (0.81) MAPTKDM4EPKMALDH1A1HTT
SCHEMBL28757507 0.70 PARP10 (0.50) MAPTKDM4EALDH1A1MAOBPARP10
SCHEMBL6466315 0.70 AR (0.59) MAPTALDH1A1HTTARMEN1
SCHEMBL15497072 0.68 F2RL3 (0.52) MAPTKDM4EALDH1A1POLBL3MBTL1
SCHEMBL7365076 0.68 KMT2A (0.69) MAPTKDM4EALDH1A1POLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050101657-A1 Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative TAKEDA CHEMICAL INDUSTRIES LTD. (JP) 2005-05-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101657-A1 Pyrrole derivatives for preventing or treating cancer sensitive to hormones; administered with luteininzing hormone releasing hormone derivative SHBG, PRLHR, FSHR MAPT 4864/4885KDM4E 1858/4885PKM 3131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.